TP53 and hepatocellular carcinoma: Compared with HBV-HCC, MASLD-HCC is associated with a high incidence of mutations in CTNNB1 over TP53. This shift in the driver mutations results in immune exclusion through the repression of the TNF receptor superfamily member 19 (TNFRSF19)-mediated senescence-associated secretory phenotype (SASP), as shown in a syngeneic immunocompetent mouse model [157].